The study of oxidative status in children with end stage renal disease on regular hemodialysis

Ahmed Mohamed Mahmoud Odima¹, Nagy Mohamed Abo Elhana¹, Wesam Salah Mohamed² and Mohamed Abd Elaziz Elgamsy¹.

Department of Pediatric Medicine¹ and Department of Clinical Pathology², Faculty of Medicine, Tanta University, Egypt.

Corresponding author: Ahmed Mohamed Mahmoud Odima; Mobile: 01008869083; Email: ahmedodeama2000@gmail.com

ABSTRACT

Background: Oxidative stress has long been demonstrated in haemodialysis patients. However, the factors influencing their oxidative status have not been characterized extensively in these patients. Despite heterogeneity in the oxidative stress levels in the CKD population, there has been little effort to measure patient oxidative stress levels before the use of any anti-oxidant therapies to optimize outcome.

Objectives: Assessment of oxidative stress and the effects of using antioxidant medications on oxidative status in children with end stage renal disease under regular hemodialysis.

Subjects and Methods: 70 children were included in this study and were categorized into 2 groups: Group (1): 35 children with ESRD on regular haemodialysis. Their ages ranged from 8 to 15 years old. They were 14 males and 21 females. All patients were undergoing haemodialysis three times per week, with each dialysis session lasting for three to four hours. Group (2): 35 healthy children with matched age and sex that were serving as control group. All patients were receiving antioxidant drugs regularly for 3 months. These antioxidant drugs were vitamin E in a dose of 5 mg/kg/day, vitamin C in a dose of 100-200 mg /day, N-Acetyl Cysteine in a dose of one sachet (200 mg) twice daily with meal. All children in both groups were subjected to: (a) complete history taking. (b) Full clinical examination. (c) Laboratory Investigations [Routine Investigations: CBC, blood urea, serum creatinine and BUN, PTH and PT, PTT and Bleeding Time. Specific Investigations: Measuring levels of 1-Interleukin-1β, tumor necrosis factor alpha, thiobarbituric acid reactive substances and malondialdehyde].

Results: There was an increase in markers of oxidative stress in children with end-stage renal disease on regular haemodialysis in the form of: 1) Increase serum level of interleukin 1β (IL-1β). 2) Increase serum level of tumor necrosis factor alpha (TNF-α). 3) Increase serum level of thiobarbituric acid reactive substances (TBARS). 4) Increase serum level of malondialdehyde (MDA). These levels were decreased with antioxidant drugs used in this study.

Conclusion: The high levels of oxidative stress markers were decreased after regular therapy by antioxidant medications for 3 months in the form of vitamin E (5 mg/kg/day), vitamin C (100-200 mg /day) and N-Acetyl Cysteine (one sachet (200 mg) twice daily with meal).

Key words: Oxidative status; End stage renal disease; Hemodialysis.

INTRODUCTION

ESRD represent the state in which a patient's renal dysfunction has progressed to the point at which homeostasis and survival can no longer be sustained with native kidney function and maximal medical management. At this point renal replacement therapies (dialysis or renal transplantation) become necessary (¹). Data from the United States Renal Data System (USRDS) revealed that in patients younger than 20 years old of age, the annual incidence of ESRD increased marginally from 13 per million in 1988 to 15 per million in 2003 (²).

The etiology of CKD in Egyptian children less than 5 years of age was comprised of parenchymatous disease in 73% of cases and obstructive etiology in 27% of cases, while after 5 years of age parenchymatous disease was 67% and obstructive etiology accounted for 33% of cases, this was explained by the possible abuse of nephrotoxic antibiotic in young infants and children (³).
either gaining an additional electron or by losing one. The unpaired electron generally increases the chemical reactivity of the atom or molecule because the atom attempts to abstract electrons from outer organic molecules in order to pair the odd electron. The extreme reactivity of oxygen-free radicals renders them capable of damaging molecular species common to all cells and tissues. A system of nutritional and endogenous enzymatic antioxidant defenses generally holds the production of free radicals in check, thus preventing "oxidant stress" and subsequent tissue damage (4).

An evidence suggests that oxidant stress may contribute to mitochondrial swelling (mitochondrial membrane permeability transition) that precedes cell death. The presence of low concentrations of H2O2 has been shown to activate the transcription factor, NF-kappa B, which can then enter the nucleus of cells, bind to DNA control elements/ and induce synthesis of specific mRNAs (5). Animal experiments have provided sample evidence that ROS play a major role in many glomerular diseases. Most of this evidence has been obtained indirectly by the detection of products of lipid peroxidation in renal tissues and by the demonstration of protective effects of administered antioxidants (6).

Oxidative stress has been demonstrated in human patients with nephritic syndrome. Because the direct quantification of reactive oxygen species is not feasible, most studies have shown increased levels of lipid peroxidation by-products, particularly malonyl di-aldehyde (MDA), in serum or erythrocytes or both (7). The body antioxidant defenses are endogenous and exogenous (dietary and therapeutic). Dietary antioxidants include vitamin E, vitamin C (L-ascorbic acid), and β carotene. Vitamin E refers to eight structurally similar compounds, α-, β-, γ-, and Δ tocopherol. The α-tocopherol has the highest biological activity and is therefore often referred to as vitamin E. The α-tocopherol and β carotene are lipid-soluble molecules, whereas vitamin C resides in the aqueous phase. Importantly, many antioxidants exhibit synergistic relationships with other antioxidants; for example, vitamin C is capable of recycling α-tocopherol (8).

PATIENTS AND METHODS

This present study was carried out at Pediatric Department, Tanta University Hospital over one year [July 2016 - April 2017]. It was approved by the Ethical Committee of the Faculty of Medicine, Tanta University. A total of 70 children were included in this study and were categorized into 2 groups: Group (1) comprised of 35 children with ESRD on regular haemodialysis. Their ages ranged from 8 to 15 years old. They were 14 males and 21 females. All patients were undergoing haemodialysis three times per week, with each dialysis session lasting for three to four hours. Group (2) included 35 healthy children with matched age and sex that were serving as control group.

Dialysis was started when GFR is equal or less than 15 ml/min. /l .73m2. Patients were dialyzed on Fresenius 4008- B dialysis machine (Germany) at blood flow rate = 2.5 x weight (kg) + 100ml/min., using polysulphone hollow fiber dialyzers suitable for the surface area of the patients (Fresenius F3 = 0.4 m2, F4 = 0.7m2, F5 = 1.0m2 and F6 = 1.2m2). Bicarbonate dialysis solutions were used. All patients were receiving supportive therapy in the form of SC. erythropoietin in a dose of 50 IU/Kg/session, IV iron dextran 76 - mg/Kg/week, oral folic acid 1 mg/day, oral calcium 1000 mg/day, oral vitamin D (one alpha) in a dose of 0.01-0.05 μg/Kg/ day and oral antihypertensive medications for hypertensive patients.

All patients were receiving antioxidant drugs regularly for 3 months. These antioxidant drugs were vitamin E in a dose of 5 mg/kg/day, vitamin C in a dose of 100-200 mg /day and N-Acetyl Cystiene in a dose of one sachet (200 mg) twice daily with meal (Coombes & Fassett 2012) (9).

All children in both groups were subjected to: (a) complete history taking including [duration of dialysis and regular drug taking]. (b) Full clinical examination. (c) Laboratory Investigations [Routine Investigations: Complete blood picture (CBC), blood urea, serum creatinine and BUN, PTH and PT, PTT and Bleeding Time. Specific Investigations: Measuring levels of 1-Interleukin-1β, tumor necrosis factor alpha, thiobarbituric acid reactive substances and malondialdehyde].

Blood sampling:

Venous blood samples were taken immediately before hemodialysis session at the first dialysis session of the week and before heparin administration. Samples were drawn in tubes with EDTA. Samples were centrifuged at 1000 x g for 15 minutes. The serum was analyzed immediately or aliquot and stored at -20.
All patients and controls were subjected to the following investigations:

(A) Routine Investigations: [Complete blood picture, Blood urea, serum creatinine, BUN, PTH, PT, PTT and Bleeding Time].

(B) Specific: Measuring levels of [Interleukin-1β, Tumor necrosis factor alpha, Thiobarbituric acid and Human Malondialdehyde by ELISA (Enzyme-Linked Immuno-sorbant Assay technique).

Statistical analysis

In addition to the descriptive data, statistical analysis was done using IBM SPSS STATISTIC VERSION 20 PROGRAM. Data were expressed as mean ± SD and analyzed using the Chi square (x²) test and the Anova test to assess the significance of difference in the levels between different parameters. P < 0.05 was accepted as significant. Coefficient (r) of two variables was also done by using Pearson Correlation Coefficient (r) with P Value Calculation.

RESULTS

Laboratory assessments of the measured parameters in the different submitted groups are presented in the following tables and figures:

- As regard to routine laboratory data, patients have significant lower values in HB, TLC, platelets count and serum albumin than control group while patients have significant higher values in serum creatinine, blood urea, BUN, PTH, PT and PTT than control group (table 1).

**Table (1):** Routine laboratory data of studied patients and controls

<table>
<thead>
<tr>
<th>Groups</th>
<th>Patients</th>
<th>Control</th>
<th>t</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>HB (g/dl)</td>
<td>Mean ± SD</td>
<td>8.837 ± 0.964</td>
<td>12.203 ± 0.510</td>
<td>-18.264</td>
</tr>
<tr>
<td>TLC (x10⁹ per cmm)</td>
<td>Mean ± SD</td>
<td>6.353 ± 1.298</td>
<td>9.446 ± 2.807</td>
<td>-5.043</td>
</tr>
<tr>
<td>Platelets (x10⁹ per liter)</td>
<td>Mean ± SD</td>
<td>213.286 ± 10.235</td>
<td>249.143 ± 18.479</td>
<td>-2.137</td>
</tr>
<tr>
<td>S. Creatinine (mg/dl)</td>
<td>Mean ± SD</td>
<td>7.854 ± 2.761</td>
<td>0.520 ± 0.196</td>
<td>15.623</td>
</tr>
<tr>
<td>Blood Urea (mg/dl)</td>
<td>Mean ± SD</td>
<td>187.571 ± 54.220</td>
<td>18.629 ± 2.777</td>
<td>18.410</td>
</tr>
<tr>
<td>BUN (mg/dl)</td>
<td>Mean ± SD</td>
<td>74.400 ± 34.641</td>
<td>7.671 ± 0.962</td>
<td>11.392</td>
</tr>
<tr>
<td>Serum Albumin (g/dl)</td>
<td>Mean ± SD</td>
<td>2.691 ± 0.276</td>
<td>4.211 ± 0.514</td>
<td>-15.407</td>
</tr>
<tr>
<td>PTT (sec)</td>
<td>Mean ± SD</td>
<td>37.514 ± 8.813</td>
<td>33.457 ± 7.370</td>
<td>2.089</td>
</tr>
<tr>
<td>PT (sec)</td>
<td>Mean ± SD</td>
<td>14.983 ± 4.542</td>
<td>12.823 ± 1.508</td>
<td>2.670</td>
</tr>
<tr>
<td>PTH (pg/ml)</td>
<td>Mean ± SD</td>
<td>350.256 ± 231.583</td>
<td>45.486 ± 11.736</td>
<td>7.776</td>
</tr>
</tbody>
</table>

**Abbreviations:** HB=haemoglobin, TLC=total leucocytic count, BUN=blood urea nitrogen, PTT=activated partial thromboplastin time, PT=prothrombin time, PTH=parathyroid hormone, t=student test.

- There were no statistically significant differences between the systolic blood pressure and diastolic blood pressure in the studied patients before and after giving antioxidant drugs(p- value>0.05) but there were significant increase in the systolic and diastolic blood pressure of patients before and after giving drugs when compared with controls(p-value<0.001) (table 2).

**Table (2):** Blood pressure of studied patients and controls

<table>
<thead>
<tr>
<th>Groups</th>
<th>Patients</th>
<th>Control</th>
<th>ANOVA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before antioxidant drugs</td>
<td>After antioxidant drugs</td>
<td>F test</td>
<td>P value</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The study of oxidative status in children with….  

---

<table>
<thead>
<tr>
<th>SBP</th>
<th>Mean ± SD</th>
<th>124.000 ± 10.901</th>
<th>123.571 ± 15.977</th>
<th>115.143 ± 10.675</th>
<th>5.367</th>
<th>0.006*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paired Samples Test</td>
<td>t</td>
<td>0.140</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>P-value</td>
<td>0.889</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>81.143 ± 9.632</td>
<td>76.000 ± 10.901</td>
<td>73.714 ± 10.596</td>
<td>4.693</td>
<td>0.011*</td>
<td></td>
</tr>
<tr>
<td>Paired Samples Test</td>
<td>t</td>
<td>2.240</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>P-value</td>
<td>0.072</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations; SBP=systolic blood pressure, DBP=diastolic blood pressure, SD=standard deviation, t=student test.

- Specific laboratory data of studied patients and controls with significant p value <0.001 for all (table 3).

Table (3): Specific laboratory data of studied patients and controls

<table>
<thead>
<tr>
<th>IL-1B (ng/ml)</th>
<th>Mean ± SD Before antioxidant drugs</th>
<th>3.858 ± 2.320</th>
<th>2.362 ± 1.086</th>
<th>0.867 ± 0.072</th>
<th>35.745</th>
<th>&lt;0.001*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paired Samples Test</td>
<td>t</td>
<td>7.060</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>P-value</td>
<td>&lt;0.001*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDA (umol/L)</td>
<td>Mean ± SD</td>
<td>2.501 ± 0.597</td>
<td>2.052 ± 0.377</td>
<td>0.808 ± 0.204</td>
<td>149.431</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Paired Samples Test</td>
<td>t</td>
<td>10.536</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>P-value</td>
<td>&lt;0.001*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TBARS (pg/ml)</td>
<td>Mean ± SD</td>
<td>3.277 ± 0.691</td>
<td>2.599 ± 0.264</td>
<td>1.833 ± 0.200</td>
<td>93.466</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Paired Samples Test</td>
<td>t</td>
<td>9.121</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>P-value</td>
<td>&lt;0.001*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNF-α (ng/ml)</td>
<td>Mean ± SD</td>
<td>3.666 ± 1.263</td>
<td>2.577 ± 0.420</td>
<td>0.922 ± 0.252</td>
<td>109.138</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Paired Samples Test</td>
<td>t</td>
<td>7.385</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>P-value</td>
<td>&lt;0.001*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations; IL-1B=interleukin 1β, MDA=malondialdehyde, TBARS=thiobarbituric acid reactive substance, TNF-α=tumor necrosis factor alpha, SD=standard deviation, t=student test.

- As regards to parathyroid hormone level, there was significant increase in patients level in comparison to controls (p value<0.001) [figure 1].
- As regard interleukin 1β level, there was significant increase in level of IL-1B in patients before giving antioxidant drugs when compared with that level 3 months after giving drugs(p value<0.001), also there was significant increase in level of IL-1B in patients before and after giving drugs when compared with controls(p value <0.001) [figure 2].
- As regard blood pressure, there were no statistically significant differences between the systolic blood pressure and diastolic blood pressure in the studied patients before and after giving antioxidant drugs(p-value>0.05) but there were significant increase in the systolic and diastolic blood pressure of patients before and after giving drugs when compared with controls(p-value<0.001) [figure 3].
- As regard thiobarbituric acid reactive substances level, there was significant increase in level of TBARS in patients before giving antioxidant drugs when compared with that level 3 months after giving drugs(p value<0.001), also there was significant increase in level of TBARS in patients before and after giving drugs when compared with controls(p value <0.001) [figure 4].
As regard tumor necrosis factor alpha level, there was significant increase in level of TNF-α in patients before giving antioxidant drugs when compared with that level 3 months after giving drugs (p value < 0.001), also there was significant increase in level of TNF-α in patients before and after giving drugs when compared with controls (p value < 0.001) [figure 5].

As regard malondialdehyde level (MDA), there was significant increase in level of MDA in patients before giving antioxidant drugs when compared with that level 3 months after giving drugs (p value < 0.001), also there was significant increase in level of MDA in patients before and after giving drugs when compared with controls (p value < 0.001) [figure 6].

As regard correlation between different parameter used in these study; there was significant negative correlation between [IL-1β level before treatment by antioxidant drugs and age (figure7), MDA level before treatment by antioxidant drugs and blood urea level (figure8), MDA level and blood urea level after treatment (figure9), TBARS level before treatment by antioxidant drugs and age (figure10), TBARS level and age after treatment (figure11), TNF-α level before treatment by antioxidant drugs and age (figure12) and TNF-α level and age after treatment (figure13)], while the correlation was significantly positive between [MDA and IL-1β before treatment (figure14), TBARS and IL-1β before treatment (figure16), TNF-α and IL-1β before treatment (figure18), TBARS and MDA before treatment (figure20), TNF-α and MDA before treatment (figure21)].
Ahmed Odima et al.

(figure 22), TNF-α and TBARS before treatment (figure 24), MDA and IL-1B after treatment (figure 15), TBARS and IL-1B after treatment (figure 17), TNF-α and IL-1B after treatment (figure 19), TBARS and MDA after treatment (figure 21), TNF-α and MDA after treatment (figure 23) and TNF-α and TBARS after treatment (figure 25).

**Figure (7):** Correlation between interleukin 1β (IL-1β) level of patients before treatment by antioxidant drugs and age.

**Figure (8):** Correlation between malondialdehyde (MDA) level of patients before treatment by antioxidant drugs and blood urea level.

**Figure (9):** Correlation between malondialdehyde (MDA) level of patients after treatment by antioxidant drugs and blood urea level.

**Figure (10):** Correlation between thiobarbituric acid reactive substances (TBARS) level of patients before treatment by antioxidant drugs and age.

**Figure (11):** Correlation between thiobarbituric acid reactive substances (TBARS) level of patients after treatment by antioxidant drugs and age.
Figure (12): Correlation between tumor necrosis factor alpha (TNF-α) level of patients before treatment by antioxidant drugs and age.

Figure (13): Correlation between tumor necrosis factor alpha (TNF-α) level of patients after treatment by antioxidant drugs and age.

Figure (14): Correlation between MDA level and IL-1B level before giving antioxidant drugs.

Figure (15): Correlation between MDA level and IL-1B level after giving antioxidant drugs.

Figure (16): Correlation between TBARS level and IL-1B level before giving antioxidant drugs.

Figure (17): Correlation between TBARS level and IL-1B level after giving antioxidant drugs.

Figure (18): Correlation between TNF-α level and IL-1B level before giving antioxidant drugs.

Figure (19): Correlation between TNF-α level and IL-1B level after giving antioxidant drugs.

Figure (20): Correlation between TBARS level and MDA level before giving antioxidant drugs.
The study of oxidative status in children with….

**Figure (21):** Correlation between TBARS level and MDA level after giving antioxidant drugs.

![Graph](image1)

**Figure (22):** Correlation between TNF-α level and MDA level before giving antioxidant drugs.

![Graph](image2)

**Figure (23):** Correlation between TNF-α level and MDA level after giving antioxidant drugs.

![Graph](image3)

**Figure (24):** Correlation between TNF-α level and TBARS level before giving antioxidant drugs.

![Graph](image4)

**Figure (25):** Correlation between TNF-α level and TBARS level after giving antioxidant drugs.

![Graph](image5)

**DISCUSSION**

Chronic uremia is considered a proinflammatory state associated with high morbidity and mortality \(^{(10)}\). Patients on regular hemodialysis have elevated oxidative stress compared to healthy matched controls. Oxidative stress may be increased because of loss of antioxidants during dialysis \(^{(11)}\), interaction between blood and dialysis membrane \(^{(12)}\), bacterial products in dialysate crossing the dialysis membrane directly or indirectly stimulating release of reactive species by neutrophils and malnutrition decreasing the uptake of dietary antioxidants \(^{(13)}\). On the basis of the evidence of elevated oxidative stress in pre-dialysis chronic kidney disease patients, it is evident that the disease itself contributes to this state \(^{(14)}\). Patients treated by renal replacement therapy are subjected to a wide range of biochemical disorders, some of which were ascribed to increased oxidative stress \(^{(15)}\).

*El shamaa et al.* \(^{(16)}\) studied that pediatric patients with end-stage renal disease undergoing hemodialysis are exposed to oxidative stress associated with an impairment of antioxidant defense and an overproduction of oxidative stress markers and they approved that oxidative stress plays a significant role in the development of inflammation in those patients.

There is currently a great interest in the assessment of antioxidant status as antioxidant depletion may contribute to a number of diseases including ESRD. In the current study, alphatochopherol (vitamin E), N-acetyl cysteine and vitamin C were used as antioxidant drugs. This is in agreement with *Coombes et al.* \(^{(9)}\) who used them in doses of 5 mg/kg/day for vitamin E, vitamin C in a dose of 100-200 mg /day and N-Acetyl Cysteine in a dose of one sachet (200 mg) twice daily with meal.

In agreement with *El shamaa et al.* \(^{(16)}\) the current study showed that there were no significant
differences between the studied groups regarding age or sex. The mean age of patients in years was 11.057 ± 2.100 while that of control group was 10.971 ± 2.294. There were no significant differences between studied patients and controls as regards weight and height. The mean weight for patients was 29.510 ± 9.541 kg while that of control group was 31.140 ± 10.719 kg. The mean height for patients was 128.110 ± 10.154 cm while that of control group was 130.331 ± 15.814 cm. In the current study 40% of patients were male while 60% of patients were female. This ratio is in agreement with Shiba et al. (17) and disagree with other studies in which the majorities were boys. For example, Jamro et al. (18), where seventy eighty confirmed cases of chronic renal failure (CRF) were included in the study. Out of them 51 were male and 29 females (M: F ratio 1.8:1). Also, in another study done by Rahman et al. (19) a total of 44 children with CRF having mean age of 8.73 ± 3.56 years old were diagnosed during study period, 30 cases (68.19%) were males and 14 cases (31.81%) were females.

Also, Lewis et al. (20) found that chronic renal failure more common in males than females due to predominance of males in renal dysplasia and obstructive uropathy that leads to renal failure. This difference in ratio may be due to the more interest of the Egyptian people for males than females who seek renal transplantation earlier than females.

In the current study, the etiologies of renal failure were congenital anomalies of kidney and urinary tract in 57.14% of cases, lupus nephritis in 22.86% of cases, steroid resistant nephrotic syndrome in 11.43% of cases and hemolytic uremic syndrome in 8.57% of cases. The National Kidney Foundation (21) reported that from birth to age 4 years, birth defects and hereditary diseases are by far the leading causes of kidney failure. Between ages 5 and 14 years, hereditary diseases continue to be the most common causes, followed closely by glomerular diseases. In the 15- to 19-years-old group, glomerular diseases are the leading cause, and hereditary diseases become rare.

In our study, the mean value of hemoglobin level for control group was statistically and significantly higher compared to patients. Similar results were published by Clermont et al. (22) who noted that chronic renal failure patients were anemic compared to healthy controls. Mean value of total leucocytic count for control group was significantly higher compared to patients. Mean value of platelets count for control group was statistically higher compared with patients. Mean values of serum albumin level in control group was significantly higher compared to patients. There were an increased concentrations of both urea, creatinine and blood urea nitrogen of patients compared to control group. This is in line with findings previously published (22, 23, 15 and 24).

There was an increased level of parathyroid hormone in patients compared to control group, this might be attributed to chronic kidney disease and MBD (mineral and bone disorders) in which there is an increased retention of phosphorus. The current result was in agreement with Kawaguchi et al. (25), Malyszko et al. (26) and Jacobson et al. (27).

As regards blood pressure, there were no statistically significant differences between the systolic blood pressure and diastolic blood pressure in the studied patients before and after giving antioxidant drugs (p value > 0.05) but there were significant increase in the systolic and diastolic blood pressure of patients before and after giving drugs when compared to controls (p value < 0.001).

In the current study, a significant increase in the level of serum interleukin 1β, malondialdehyde, thiobarbituric acid reactive substances, tumor necrosis factor alpha levels in patients before giving antioxidant drugs when compared to these levels 3 months after giving antioxidant drugs. These results can be attributed to the increased oxidative stress in patients with ESRD. These results were in agreement with Penuchant et al. (28) and Jackson et al. (29) who studied oxidative stress markers in children with ESRD, they concluded that there was an increase in oxidative stress in children on maintenance dialysis. This could be attributed to the highly reduced activity of the enzymatic antioxidant defense system in plasma of pediatric dialysis patients. In addition, there was significant increase in the levels of these indices in patients before and after giving antioxidant drugs when compared to control group. This is consistent with findings previously published by Elshamaa et al. (15) and Samouilidou et al. (30) who studied oxidative stress markers and C - reactive protein in pediatric patients on hemodialysis and found that total antioxidant capacity and MDA levels were significantly higher in children on HD than in the healthy controls. They concluded that there was an increase in oxidative stress in children on HD and that the susceptibility to oxidative stress is strongly related to the level of MDA produced in plasma. There was a significant increase in interleukin 1 β and tumor necrosis factor alpha levels of patients.
when compared to control group. This is in agreement with Ghobrial et al. (31) who studied oxidative stress in Egyptian hemodialysis children and found that serum level of TNF-α and IL-1β were significantly higher in children on hemodialysis as compared to the control group. They concluded that the levels of cytokines are high in pediatric patients on hemodialysis, which reflects a state of oxidative stress.

The current study also showed a significant increase in level of malondialdehyde level of patients when compared to control group. This is in agreement with Zwolinska et al. (32) who studied lipid peroxidation and antioxidant enzymes in children on dialysis. They reported that the erythrocyte MDA concentrations in ESRD children were significantly higher than in healthy subjects.

In the current study, there was significant increase in lipid peroxidation represented by thiobarbituric acid reactive substances in patients when compared to control group. This is in agreement with Toborek et al. (33) who studied effect of hemodialysis on lipid peroxidation and antioxidant system in patients with chronic renal failure. They found that hemodialysis produce increased lipid peroxidation.

As regards correlations between indices of oxidative stress and different studied demographic and laboratory data, there was significant negative correlation between TNF-α, IL-1β and TBARS levels of patients before treatment by antioxidants drugs and age. There was a significant negative correlation between TNF-α and TBARS levels of patients after treatment by antioxidant drugs and age. There was significant negative correlation between MDA level of patients before & after treatment by antioxidant drugs and blood urea level. There was a significant positive correlation between MDA, TBARS and TNF-α levels of patients before treatment by antioxidant drugs and IL-1β level. There was significant positive correlation between TBARS and TNF-α levels of patients before treatment by antioxidant drugs and MDA level. There was significant positive correlation between TBARS and TNF-α levels of patients after treatment by antioxidant drugs and IL-1β level. There was significant positive correlation between TBARS and TNF-α levels of patients after treatment by antioxidant drugs and TBARS level. There were no available comparable data in previously published articles on pediatric patients with ESRD on regular hemodialysis.

In conclusion the current study showed an increase in markers of oxidative stress in children with end-stage renal disease on regular hemodialysis in the form of:
- Increase serum level of interleukin 1β (IL-1β).
- Increased serum level of tumor necrosis factor alpha (TNF-α).
- Increased serum level of thio-barbituric acid reactive substances (TBARS).
- Increased serum level of malondialdehyde (MDA).

These oxidative stress markers were decreased after regular therapy by antioxidant medications for 3 months in the form of vitamin E (5 mg/kg/day), vitamin C (100-200 mg /day) and N-Acetyl Cysteine ( one sachet 200 mg twice daily with meal). Therefore, supplementation of antioxidant vitamins is required as an adjuvant therapy in children with end stage renal disease and children with chronic renal failure on regular hemodialysis.

REFERENCES


Nephrology Dialysis Transplantation, 15(8): 1127-1132.


